EuroBiotech: More Articles of Note

> Addex (SWX:ADXN) moved its R&D unit to the life science cluster that has been set up at Merck Serono's former campus in Geneva, Switzerland. The Addex R&D unit joins teams from the Swiss Federal Institute of Technology, University of Geneva and the Human Brain Project at the 40,000-square-meter campus. Release

> Pfizer ($PFE) dealt its reputation in the United Kingdom another blow by revealing it is to close its 120-person R&D site in Cambridge. The Big Pharma framed the decision as part of a consolidation of its neuroscience and pain R&D infrastructure. Cambridge, as a growing drug research hub, is better placed than Sandwich was to absorb R&D staffers jettisoned by Pfizer, but the move will definitely cause short-term disruption. Whether in the longer term ex-employees pick up IP from Pfizer and set up their own biotechs, as happened following the Sandwich cuts, remains to be seen. FierceBiotech

> United Therapeutics ($UTHR) dropped its licensing agreement with Pluristem Therapeutics ($PSTI). The move means Israeli cell therapy specialist Pluristem has regained full rights to PLX-PAD in pulmonary arterial hypertension. United Therapeutics made the decision after getting a look at data from the first three patients treated in a Phase I trial. While Pluristem talked up the safety profile and efficacy trend generated in the study, United Therapeutics thinks it is best served by walking away from the program. Release

Galapagos ($GLPG) posted Phase II data on filgotinib, the oral JAK inhibitor AbbVie ($ABBV) walked away from earlier this year. The data showed that filgotinib outperformed a placebo in terms of inducing remission in people with Crohn's disease, positioning Galapagos to move the drug into Phase III and strengthening its hand as it searches for a partner to replace AbbVie. "Given filgotinib's unique clinical benefit in Crohn's to-date, providing at the very least a first-to-market advantage in the indication, we believe these data should boost the likelihood of successfully signing a new partnership deal in the near future," Jefferies analyst Peter Welford wrote in a note to investors. FierceBiotech

> MorphoSys (ETR:MOR) posted data on MOR202 and MOR208. Data on MOR202, the multiple myeloma drug dropped by Celgene ($CELG) earlier this year, come from an ongoing Phase I/II trial and back up MorphoSys' belief that the drug can be infused far faster than rival anti-CD38 drugs. The MOR208 data come from Phase II trials in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia. Release | More

> Sofinnova Partners rounded up €300 million ($325 million) to invest in up to 20 biotechs, two-thirds of which are expected to be based in Europe. The sum, which is €50 million more than Sofinnova set out to raise, gives the Paris-based VC shop the financial clout to continue its work of identifying, nurturing and financing early-stage biotechs. Recent successes for the company include the sale of Glycovaxyn and IPO of DBV Technologies ($DBVT). FierceBiotech

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.